- Home
- CANF vs APRE Comparison
CANF vs APRE Comparison
Compare CANF & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- APRE
- Stock Information
- Founded
- CANF 1994
- APRE 2006
- Country
- CANF Israel
- APRE United States
- Employees
- CANF N/A
- APRE N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CANF Health Care
- APRE Health Care
- Exchange
- CANF Nasdaq
- APRE Nasdaq
- Market Cap
- CANF 14.4M
- APRE 15.8M
- IPO Year
- CANF N/A
- APRE 2019
- Fundamental
- Price
- CANF $1.48
- APRE $3.05
- Analyst Decision
- CANF Strong Buy
- APRE Strong Buy
- Analyst Count
- CANF 2
- APRE 2
- Target Price
- CANF $14.00
- APRE $15.50
- AVG Volume (30 Days)
- CANF 1.2M
- APRE 22.6K
- Earning Date
- CANF 12-31-2024
- APRE 11-07-2024
- Dividend Yield
- CANF N/A
- APRE N/A
- EPS Growth
- CANF N/A
- APRE N/A
- EPS
- CANF N/A
- APRE N/A
- Revenue
- CANF $667,000.00
- APRE $1,310,839.00
- Revenue This Year
- CANF $409.56
- APRE $134.21
- Revenue Next Year
- CANF N/A
- APRE N/A
- P/E Ratio
- CANF N/A
- APRE N/A
- Revenue Growth
- CANF N/A
- APRE 130.31
- 52 Week Low
- CANF $1.29
- APRE $2.15
- 52 Week High
- CANF $4.69
- APRE $8.85
- Technical
- Relative Strength Index (RSI)
- CANF 35.58
- APRE 43.20
- Support Level
- CANF $1.30
- APRE $3.02
- Resistance Level
- CANF $1.72
- APRE $3.39
- Average True Range (ATR)
- CANF 0.18
- APRE 0.30
- MACD
- CANF -0.01
- APRE -0.01
- Stochastic Oscillator
- CANF 17.92
- APRE 3.85
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.